"Glutaminase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D005972
|
| MeSH Number(s) |
D08.811.277.087.483
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glutaminase".
Below are MeSH descriptors whose meaning is more specific than "Glutaminase".
This graph shows the total number of publications written about "Glutaminase" by people in this website by year, and whether "Glutaminase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glutaminase" by people in Profiles.
-
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer. 2024 Oct; 5(10):1515-1533.
-
Mitochondrial reprogramming by activating OXPHOS via glutamine metabolism in African American patients with bladder cancer. JCI Insight. 2024 Sep 10; 9(17).
-
HuR controls glutaminase RNA metabolism. Nat Commun. 2024 Jul 04; 15(1):5620.
-
The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Adv. 2024 05 14; 8(9):2312-2325.
-
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica. 2023 06 01; 108(6):1616-1627.
-
In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. Sci Adv. 2022 12 16; 8(50):eabp8293.
-
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418.
-
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. Clin Cancer Res. 2022 08 02; 28(15):3248-3255.
-
Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer. Oncogene. 2022 Feb; 41(8):1140-1154.
-
A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proc Natl Acad Sci U S A. 2021 03 30; 118(13).